- Conditions
- Stage IB-IIIA Non-small Cell Lung Carcinoma
- Interventions
- AZD9291 80 mg/40 mg, Placebo AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 682 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Santa Monica, California • Santa Rosa, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 40
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hepatocellular Carcinoma
- Interventions
- TheraSphere®, Sorafenib
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • New York, New York
- Conditions
- Acute Submassive Pulmonary Embolism
- Interventions
- The Bashir™ Endovascular Catheter (BEC
- Device
- Lead sponsor
- Temple University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Interventions
- CHS-388, Pembrolizumab, Toripalimab
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 18
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- NAL ER, Placebo
- Drug
- Lead sponsor
- Trevi Therapeutics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 19
- States / cities
- Newport Beach, California • Palm Springs, California • Redding, California + 16 more
- Conditions
- Emphysema
- Interventions
- Spiration Valve System, Medical Management
- Device · Other
- Lead sponsor
- Olympus Corporation of the Americas
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 32
- States / cities
- Fort Smith, Arkansas • Riverside, California • San Diego, California + 28 more
- Conditions
- Chronic Obstructive Pulmonary Disease, Emphysema
- Interventions
- Effectiveness of Lung Reduction Therapy
- Procedure
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- Up to 75 Years · Male only
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2000
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Lung Transplant, CMV
- Interventions
- Letermovir, Valganciclovir
- Drug
- Lead sponsor
- Fernanda P Silveira, MD, MS
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Spinal Cord Injuries, Respiratory Complication
- Interventions
- Jamboxx Respiratory Therapy Device, Jamboxx Musical Device
- Device
- Lead sponsor
- My Music Machines Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Albany, New York
- Conditions
- Emphysema or COPD, Emphysema, COPD
- Interventions
- Implantable Artificial Bronchus
- Device
- Lead sponsor
- Pulmair Medical, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- San Francisco, California • Chicago, Illinois • Boston, Massachusetts
- Conditions
- Lung Carcinoma, Malignant Respiratory Tract Neoplasm, Metastatic Malignant Neoplasm in the Lung
- Interventions
- Biphasic Positive Airway Pressure, Computed Tomography, Continuous Positive Airway Pressure, Deep Inspiration Breath Hold, Radiation Therapy Treatment Planning and Simulation, Stereotactic Body Radiation Therapy
- Device · Procedure · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- Atezolizumab
- Drug
- Lead sponsor
- Liza Villaruz, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Pittsburgh, Pennsylvania
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- Pemetrexed, Cisplatin, Cixutumumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Hackensack, New Jersey • Portland, Oregon + 2 more
- Conditions
- Cardiopulmonary Disease
- Interventions
- Echocardiography, Pulmonary Gas Exchange
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Ventricular Tachycardia, Premature Ventricular Contraction, Stroke
- Interventions
- DOAC, Aspirin
- Drug
- Lead sponsor
- Kansas City Heart Rhythm Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 4
- States / cities
- Kansas City, Kansas • Overland Park, Kansas • The Bronx, New York + 1 more
- Conditions
- Pre-Bronchiolitis Obliterans Syndrome
- Interventions
- ARINA-1, Standard of care only
- Drug · Other
- Lead sponsor
- Renovion, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more
- Conditions
- Cytomegalovirus Infections, Transplant-Related Disorder
- Interventions
- Letermovir 480 MG [Prevymis]
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Advanced Non Small Cell Lung Cancer
- Interventions
- Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects), Part A - AZD9291 in combination with intermittent selumetinib, Part A - AZD9291 in combination with MEDI4736, Part B - AZD9291 in combination with AZD6094, Part B - AZD9291 in combination with selumetinib, Part B - AZD9291 in combination with MEDI4736, Part C - AZD6094 monotherapy (Japan only), Part C - AZD9291 in combination with AZD6094 (Japan only), Part D - AZD9291 in combination with AZD6094
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Acute Myocardial Infarction
- Interventions
- LCZ696 (sacubitril/valsartan), Ramipril, Placebo of LCZ696, Placebo of ramipril, Valsartan, Placebo of valsartan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,669 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 74 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- olodaterol, tiotropium
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 7,903 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 117
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Florence, Alabama + 100 more
- Conditions
- Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
- Interventions
- Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Relapsed/Refractory Small Cell Lung Cancer
- Interventions
- Tarlatamab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Newark, Delaware + 13 more
- Conditions
- Hermansky Pudlak Syndrome, Interstitial Lung Disease
- Interventions
- Pirfenidone
- Drug
- Lead sponsor
- Jesse Roman
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Atelectases, Postoperative Pulmonary
- Interventions
- Digital Incentive Spirometer, Jamboxx Respiratory Therapy Device
- Device
- Lead sponsor
- My Music Machines Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Albany, New York